Linda A. Johnson
This image provided by Novo Nordisk on Friday, June 4, 2021 shows an injection pen for the company s semaglutide medication, named Wegovy. On Friday, the Food and Drug Administration said this new version of a popular diabetes medicine could be sold as a weight-loss drug in the U.S. (Novo Nordisk via AP) June 04, 2021 - 1:20 PM
Regulators on Friday said a new version of a popular diabetes medicine could be sold as a weight-loss drug in the U.S.
The Food and Drug Administration approved Wegovy, a higher-dose version of Novo Nordiskâs diabetes drug semaglutide, for long-term weight management.
Wegovy, made by Danish drugmaker Novo Nordisk, contains semaglutide, a synthesized version of a gut hormone that curbs appetite, and was approved by the FDA on Friday.
Regulators on Friday said a new version of a popular diabetes medicine could be sold as a weight-loss drug in the U.S. The Food and Drug Administration approved Wegovy, a higher-dose version of Novo Nordisk’s diabetes drug semaglutide. In company-funded studies, participants taking Wegovy had average weight loss of 15%, about 34 pounds (15.3 kilograms). […]
The FDA approved of new drug, Wegovy, to be sold in the U.S. and marketed for weight loss. The drug has been modified from Novo Nordisk s diabetes drug semaglutide.